Our Approach
The standards behind institutional-grade cannabis market intelligence
Cannabis Investor News delivers the same caliber of data infrastructure that institutional desks rely on for covered sectors — applied to the cannabis market. Our platform aggregates regulatory filings, exchange feeds, macroeconomic indicators, and international datasets through a proprietary multi-source framework designed for accuracy, speed, and auditability.
Editorial Standards
Regulatory-Grade Sources
All financial data originates from regulatory filings, government databases, and exchange-level feeds. We apply the same sourcing standards used by sell-side research desks at major financial institutions.
Analysis, Not Advice
Cannabis Investor News publishes proprietary market analysis — including the CIN Cannabis Market Health Index, opportunity scoring, and custom research reports — alongside third-party Wall Street consensus data that we aggregate but do not originate. Our analysis reflects CIN’s editorial perspective on publicly available data. It is not personalized investment advice, and we are not a registered investment advisor. All content is informational and should be evaluated alongside your own research and professional counsel.
Full Independence
We maintain no affiliations with broker-dealers, cannabis operators, ETF issuers, or regulators. We have no revenue relationships with any company in our coverage universe. Editorial decisions are driven solely by investor relevance.
Real-Time Transparency
When data is delayed, estimated, or unavailable, we disclose it. Update timestamps are displayed on every data page. If something changes, you see it as it happens.
Data Architecture
Real-time and near-real-time pricing for all 28 tracked securities across US exchanges, Canadian markets, and OTC venues. Our multi-source pricing engine cross-references exchange feeds and market data providers to ensure accuracy, with automatic fallback logic when primary sources experience delays.
Price history spans five years of weekly closing data, enabling long-term technical and trend analysis across the full coverage universe.
Financial statements are sourced directly from machine-readable regulatory filings — the same structured data feeds used by Bloomberg Terminal, FactSet, and S&P Capital IQ. We do not rely on third-party aggregators for fundamental data.
Coverage includes income statements, balance sheets, and cash flow data for all filing companies. Capital markets activity — debt issuances, equity raises, convertible instruments, and restructurings — is systematically extracted from regulatory disclosure filings and classified using proprietary rules.
Consensus ratings, price targets, and valuation multiples are aggregated from sell-side analyst coverage. Key metrics include P/S, P/B, EV/EBITDA, forward P/E, and short interest — the same valuation framework used in institutional equity research.
Insider transaction data is sourced from Form 4 filings, providing transparency into executive buying, selling, and option exercises across the coverage universe.
Cannabis equities do not trade in a vacuum. We track the macro variables that most directly influence sector valuations: Treasury yields, equity volatility, broad market indices, and dollar strength — all sourced from central bank and government statistical releases.
Our global module covers cannabis markets across 13 countries, drawing on data from multilateral institutions including the United Nations and the World Bank to provide regulatory context and international market sizing.
Daily market analysis and custom research reports are generated using proprietary AI models that ingest the full spectrum of our structured data — pricing, filings, analyst consensus, macro indicators, and capital markets activity — to produce institutional-quality editorial commentary.
AI-generated content is clearly labeled. All factual claims are grounded in the underlying data; the models do not access unpublished information. Custom research reports follow the same institutional format used by major sell-side firms: Executive Summary, Market Context, Core Analysis, Risk Factors, and Conclusion.
Our Commitments
- We source exclusively from regulatory filings, exchange data, and government statistical agencies
- Our proprietary analysis reflects CIN’s editorial perspective; Wall Street consensus data is aggregated from third-party sources and not originated by CIN
- We have no financial relationships with any company in our coverage universe
- We disclose data delays, limitations, and sourcing on every page
- We are not registered with the SEC, FINRA, or any regulatory body
- AI-generated content is always labeled and based solely on our structured data inputs
Important Disclosures
OTC Securities. Several cannabis companies in our coverage universe trade on over-the-counter markets. OTC equities may experience wider spreads, lower liquidity, and intermittent pricing delays compared to exchange-listed securities.
Cross-Border Filings. Companies filing with Canadian securities regulators may have limited data availability through US regulatory databases. We supplement these with available public disclosures.
AI-Assisted Content. AI-generated articles and research reports may contain analytical errors. They are intended as starting points for further due diligence — not as definitive investment analysis. Always verify independently.